User menu

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing-remitting Multiple Sclerosis (ASIIMS) trial

Bibliographic reference Gonsette, Richard E. ; Sindic, Christian ; D'hooghe, Marie B. ; De Deyn, Peter-Paul ; Medaer, Robert ; et. al. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing-remitting Multiple Sclerosis (ASIIMS) trial. In: Multiple Sclerosis : clinical and laboratory research, Vol. 16, no. 4, p. 455-462 (2010)
Permanent URL http://hdl.handle.net/2078.1/33964
  1. Cross Anne H, Manning Pamela T, Keeling Richard M, Schmidt Robert E, Misko Thomas P, Peroxynitrite formation within the central nervous system in active multiple sclerosis, 10.1016/s0165-5728(98)00078-2
  2. Becker Bernhard F., Towards the physiological function of uric acid, 10.1016/0891-5849(93)90143-i
  3. Gonsette R.E., Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity, 10.1016/j.jns.2008.06.029
  4. Hooper D. C., Spitsin S., Kean R. B., Champion J. M., Dickson G. M., Chaudhry I., Koprowski H., Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis, 10.1073/pnas.95.2.675
  5. Spitsin S, Hooper D C, Mikheeva T, Koprowski H, Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins, 10.1177/135245850100700305
  6. Rentzos M., Nikolaou C., Anagnostouli M., Rombos A., Tsakanikas K., Economou M., Dimitrakopoulos A., Karouli M., Vassilopoulos D., Serum uric acid and multiple sclerosis, 10.1016/j.clineuro.2005.08.004
  7. Koch Marcus, De Keyser Jacques, Uric acid in multiple sclerosis, 10.1179/016164106x98215
  8. Hooper D. C., Bagasra O., Marini J. C., Zborek A., Ohnishi S. T., Kean R., Champion J. M., Sarker A. B., Bobroski L., Farber J. L., Akaike T., Maeda H., Koprowski H., Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: Implications for the treatment of multiple sclerosis, 10.1073/pnas.94.6.2528
  9. Ames B. N., Cathcart R., Schwiers E., Hochstein P., Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis., 10.1073/pnas.78.11.6858
  10. Koprowski Hilary, Spitsin Sergei V., Hooper D. Craig, Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite, 10.1002/1531-8249(200101)49:1<139::aid-ana28>3.0.co;2-a
  11. McDonald W. Ian, Compston Alistair, Edan Gilles, Goodkin Donald, Hartung Hans-Peter, Lublin Fred D., McFarland Henry F., Paty Donald W., Polman Chris H., Reingold Stephen C., Sandberg-Wollheim Magnhild, Sibley William, Thompson Alan, Van Den Noort Stanley, Weinshenker Brian Y., Wolinsky Jerry S., Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis, 10.1002/ana.1032
  12. Ebers George C, Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, 10.1016/s0140-6736(98)03334-0
  13. , Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, 10.1212/wnl.43.4.655
  14. Freedman L. S., Tables of the number of patients required in clinical trials using the logrank test, 10.1002/sim.4780010204
  15. Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), 10.1212/wnl.33.11.1444
  16. Cutter G. R., Development of a multiple sclerosis functional composite as a clinical trial outcome measure, 10.1093/brain/122.5.871
  17. Lin D. Y., Wei L. J., Yang I., Ying Z., Semiparametric regression for the mean and rate functions of recurrent events, 10.1111/1467-9868.00259
  18. Ramsaransing G. S. M., Heersema D. J., De Keyser J., Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis, 10.1111/j.1468-1331.2005.01009.x
  19. Drulović Jelena, Dujmović Irena, Stojsavljević Nebojša, Mesaroš Šarlota, Andjelković Slobodanka, Miljković Djordje, Perić Vesna, Dragutinović Gradimir, Marinković Jelena, Lević Zvonimir, Stojković Marija Mostarica, Uric acid levels in sera from patients with multiple sclerosis, 10.1007/s004150170246
  20. Toncev G., Milicic B., Toncev S., Samardzic G., Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction, 10.1046/j.1468-1331.2002.00384.x
  21. Sotgiu S., Pugliatti M., Sanna A., Sotgiu A., Fois M.L., Arru G., Rosati G., Serum uric acid and multiple sclerosis, 10.1007/s100720200059
  22. Deretzi G., Mult Scler, 9, S100 (2003)
  23. Mostert Jop P., Ramsaransing Geeta S.M., Heersema Dorothea J., Heerings Marco, Wilczak Nadine, De Keyser Jacques, Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses, 10.1016/j.jns.2004.12.008
  24. Guerrero A. L., Martín-Polo J., Laherrán E., Gutiérrez F., Iglesias F., Tejero M. A., Rodríguez-Gallego M., Alcázar C., Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment, 10.1111/j.1468-1331.2008.02087.x
  25. Tsakiri A., Mult Scler, 14, S289 (2008)
  26. Constantinescu C S, Freitag P, Kappos L, Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis, 10.1177/135245850000600603
  27. Toncev G., Mult Scler, 13, S90 (2007)
  28. Handouk Y., Mult Scler, 14, S281 (2008)
  29. Scott G. S., Spitsin S. V., Kean R. B., Mikheeva T., Koprowski H., Hooper D. C., Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors, 10.1073/pnas.212645999
  30. Church W.H., Ward V.L., Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation, 10.1016/0361-9230(94)90285-2
  31. Fitzmaurice Paul S., Ang Lee, Guttman Mark, Rajput Ali H., Furukawa Yoshiaki, Kish Stephen J., Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease, 10.1002/mds.10486
  32. Hensley K., J Neurosci, 18, 8126 (1998)
  33. Flint Beal M., Matson Wayne R., Storey Elsdon, Milbury Paul, Ryan Elizabeth A., Ogawa Tatsuo, Bird Edward D., Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex, 10.1016/0022-510x(92)90191-m
  34. Langemann H., Kabiersch A., Newcombe J., Measurement of Low-Molecular Weight Antioxidants, Uric Acid, Tyrosine and Tryptophan in Plaques and White Matter from Patients with Multiple Sclerosis, 10.1159/000116835
  35. van Horssen J., Schreibelt G., Drexhage J., Hazes T., Dijkstra C.D., van der Valk P., de Vries H.E., Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression, 10.1016/j.freeradbiomed.2008.09.023
  36. Kieseier Bernd C., Hartung Hans-Peter, Interferon-β and neuroprotection in multiple sclerosis—Facts, hopes and phantasies, 10.1016/j.expneurol.2006.09.007
  37. Schwartz M., London A., Shechter R., Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: The role of innate immunity, 10.1016/j.neuroscience.2008.12.013
  38. Barnett Michael H., Parratt John D. E., Cho Eun-Sook, Prineas John W., Immunoglobulins and complement in postmortem multiple sclerosis tissue, 10.1002/ana.21524
  39. Nguyen Truyen, Nioi Paul, Pickett Cecil B., The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative Stress, 10.1074/jbc.r900010200
  40. Vamos Eniko, Pardutz Arpad, Klivenyi Peter, Toldi Jozsef, Vecsei Laszlo, The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection, 10.1016/j.jns.2009.02.326
  41. Aboul-Enein Fahmy, Rauschka Helmut, Kornek Barbara, Stadelmann Christine, Stefferl Andreas, Brück Wolfgang, Lucchinetti Claudia, Schmidbauer Manfred, Jellinger Kurt, Lassmann Hans, Preferential Loss of Myelin-Associated Glycoprotein Reflects Hypoxia-Like White Matter Damage in Stroke and Inflammatory Brain Diseases, 10.1093/jnen/62.1.25
  42. Mháille Aoife Ní, McQuaid Stephen, Windebank Anthony, Cunnea Paula, McMahon Jill, Samali Afshin, FitzGerald Una, Increased Expression of Endoplasmic Reticulum Stress-Related Signaling Pathway Molecules in Multiple Sclerosis Lesions, 10.1097/nen.0b013e318165b239
  43. Baker David, Pryce Gareth, The Endocannabinoid System and Multiple Sclerosis, 10.2174/138161208785740036
  44. Spitsin S, Hooper D C, Leist T, Streletz L J, Mikheeva T, Koprowski H, Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease, 10.1177/135245850100700507
  45. Toncev G., Neurology, 94, A385 (2005)
  46. Markowitz Clyde E., Spitsin Sergei, Zimmerman Vanessa, Jacobs Dina, Udupa Jayaram K., Hooper D. Craig, Koprowski Hilary, The Treatment of Multiple Sclerosis with Inosine, 10.1089/acm.2008.0513
  47. Offen Daniel, Gilgun-Sherki Yossi, Melamed Eldad, The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy, 10.1007/s00415-004-0348-9
  48. Mirshafiey Abbas, Mohsenzadegan Monireh, Antioxidant therapy in multiple sclerosis, 10.1080/08923970802331943